Datapoint: Merck’s Prevymis Scores New CMV Nod

The FDA on June 6 approved a new indication for Merck’s Prevymis (letermovir). It can now be used to prevent cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients. The oral antiviral was first approved in 2017 to prevent CMV in CMV-seropositive recipients of allogenic hematopoietic stem cell transplants. As a preventive agent against CMV, Prevymis currently holds covered or better status for 82% of all insured lives under the pharmacy benefit. About 19% of lives have preferred access to Prevymis.

SOURCE: MMIT Analytics, as of 6/7/23

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 26

Datapoint: Is Medicaid Expansion Coming to Mississippi?

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 22

Datapoint: Baystate to Sell Health Plan to Point32Health

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today